Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence

American Journal of Alzheimer's Disease and other Dementias

Volumn 26, Issue 3, 2011, Pages 169-183

  Henry, Genevieve ^a   Williamson, Deena ^b   Tampi, Rajesh R ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Masonicare   (United States)

Author keywords

antidepressants; behavioral and psychological symptoms of dementia; dementia; selective serotonin reuptake inhibitors; trazodone

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; PAROXETINE; PERPHENAZINE; PIRACETAM; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; DEMENTIA; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MULTIINFARCT DEMENTIA; REVIEW; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 79955821239     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317511402051     Document Type: Review

References (34)

1. Lawlor B. Managing behavioural and psychological symptoms in dementia. Br J Psychiatry. 2002 ; 181: 463-465. (Pubitemid 35440668)
2. Bharucha AJ, Rosen J., Mulsant BH, Pollock BG Assessment of behavioral and psychological symptoms of dementia. CNS Spectr. 2002 ; 7 (11). 797-802. (Pubitemid 36765054)
3. Lyketsos CG, Steinberg M., Tschanz JT, Norton MC, Steffens DC, Breitner JC Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am J Psychiatry. 2000 ; 157 (5). 708-714. (Pubitemid 30249648)
4. Margallo-Lana M., Swann A., O'Brien J., et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry. 2001 ; 16 (1). 39-44. (Pubitemid 32111815)
5. Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry. 2002 ; 52 (3). 243-252. (Pubitemid 35232091)
6. Burns A., Jacoby R., Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry. 1990 ; 157: 72-76 ; 92-94. (Pubitemid 20208663)
7. Lanari A., Amenta F., Silvestrelli G., Tomassoni D., Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev. 2006 ; 127 (2). 158-165. (Pubitemid 43165614)
8. Ballard C., Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs. 2010 ; 24 (9). 729-739.
9. Nyth AL, Gottfries CG The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990 ; 157: 894-901.
10. Olafsson K., Jørgensen S., Jensen HV, Bille A., Arup P., Andersen J. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand. 1992 ; 85 (6). 453-456.
11. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1997 ; 9 (4). 591-593. (Pubitemid 28029755)
12. Magai C., Kennedy G., Cohen CI, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry. 2000 ; 8 (1). 66-74. (Pubitemid 30036843)
13. Gaber S., Ronzoli S., Bruno A., Biagi A. Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr Suppl. 2001 ; 7: 159-162. (Pubitemid 32727480)
14. Lanctôt KL, Herrmann N., van Reekum R., Eryavec G., Naranjo CA Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry. 2002 ; 17 (6). 531-541. (Pubitemid 34678705)
15. Pollock BG, Mulsant BH, Rosen J., et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002 ; 159 (3). 460-465. (Pubitemid 34184743)
16. Moretti R., Torre P., Antonello RM, Cazzato G., Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003 ; 49 (1). 13-19. (Pubitemid 35477963)
17. Lyketsos CG, DelCampo L., Steinberg M., et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003 ; 60 (7). 737-746. (Pubitemid 36818637)
18. Finkel SI, Mintzer JE, Dysken M., Krishnan KR, Burt T., McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004 ; 19 (1). 9-18. (Pubitemid 38180687)
19. Deakin JB, Rahman S., Nestor PJ, Hodges JR, Sahakian BJ Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004 ; 172 (4). 400-408. (Pubitemid 38650975)
20. Pollock BG, Mulsant BH, Rosen J., et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007 ; 15 (11). 942-952.
21. Siddique H., Hynan LS, Weiner MF Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry. 2009 ; 70 (6). 915-918.
22. Weintraub D., Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry. 2010 ; 18 (4). 332-340.
23. Culo S., Mulsant BH, Rosen J., et al. Treating neuropsychiatric symptoms in dementia with lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010 ; 24: 360-364.
24. Sultzer DL, Gray KF, Gunay I., Berisford MA, Mahler ME A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997 ; 5 (1). 60-69. (Pubitemid 27021084)
25. Teri L., Logsdon RG, Peskind E., et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000 ; 55 (9). 1271-1278.
26. Sultzer DL, Gray KF, Gunay I., Wheatley MV, Mahler ME Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia ? J Am Geriatr Soc. 2001 ; 49 (10). 1294-1300. (Pubitemid 33015205)
27. Lebert F., Stekke W., Hasenbroekx C., Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004 ; 17 (4). 355-359. (Pubitemid 38721158)
28. Palmer AM, Stratmann GC, Procter AW, Bowen DM Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol. 1988 ; 23 (6). 616-620.
29. Mintzer J., Brawman-Mintzer O., Mirski DF, et al. Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry. 1998 ; 44 (9). 918-921. (Pubitemid 28520232)
30. Zubenko GS Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology. 1992 ; 6 (2). 77-93.
31. Pollock BG, Mulsant BH, Sweet R., et al. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. J Am J Geriatr Psychiatry. 1997 ; 5 (1). 70-78.
32. Sparks DL, Markesbery WR Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol. 1991 ; 48 (8). 796-799.
33. Swartz JR, Miller BL, Lesser IM, Darby AL Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997 ; 58 (5). 212-216. (Pubitemid 27242008)
34. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005 ; 293 (5). 596-608. (Pubitemid 40171242)